In this pilot study, we analysed serum biomarker concentrations at multiple time points (<12 h, 24 h, 72 h, 7 days) post-CA in comatose out-of-hospital CA patients included in the ghrelin in coma (GRECO) trial. The gene discussed is GHRL; the disease is type 2 diabetes mellitus.